This move is archived. Current quotes and coverage live on the stock page.
Get HBP alerts:
Helix BioPharma Corp. faces a challenging day in the market as its stock price takes a hit.
Helix BioPharma Corp. (HBP.TO) is experiencing a downturn today, with its stock price falling by 2.10% to close at CA$1.40. This decline raises concerns among investors about the company's financial stability and future prospects.
Advertisement
Helix BioPharma Corp.
HBP.TO
HBP.TO
Helix BioPharma Corp.
WealthAwesomeMarket cap
$151.99M
52W high
$5.40
52W low
$1.10
1W change
-3.00%
Beta
-0.35
Analyst Price Targets
Based on analyst covering HBP
Wall Street analysts forecast HBP stock price to rise 28.9% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$2.50
+28.9% Upside
Current Price
C$1.94
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on HBP's historical volatility
30-Day Vol
40.0%
Annualized
90-Day Vol
58.1%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$2.32
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$2.06 | C$1.79 โ C$2.36 |
| 60 trading days | C$2.19 | C$1.80 โ C$2.66 |
| 90 trading days | C$2.32 | C$1.83 โ C$2.95 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should closely monitor Helix BioPharma's financial health and strategic plans, especially in light of today's stock performance.
Helix BioPharma Corp. Market Cap
With a market cap of CA$109.22 million, Helix BioPharma's stock is under pressure amid investor uncertainty.
Bull case
If Helix BioPharma can secure the necessary financing to advance its projects, it may regain investor confidence and drive future growth.
Bear case
Ongoing financial instability and a lack of significant news could further erode investor trust, leading to more declines in the stock price.
Market Performance Overview
Advertisement
Today, Helix BioPharma Corp. (HBP.TO) saw its stock price drop by 2.10%. This decline may reflect investor concerns regarding the company's financial stability, especially in the absence of significant news or updates.
Investor Sentiment
With a market cap of CA$109.22 million, the current downturn raises questions about Helix BioPharma's ability to attract investment. Investors are advised to keep an eye on upcoming financial results and strategic announcements that could impact the stock's trajectory. For more details on the company's financials, check out the Helix BioPharma Corp. stock page.
Future Outlook
As Helix BioPharma continues to navigate its financial landscape, the potential for recovery hinges on its ability to secure funding and advance its projects. Investors should remain vigilant and consider the implications of today's performance on future investments.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile โโ Reviewed by Certified Financial Professionals
This content has been reviewed by CFAยฎ charterholders and Certified Financial Planners (CFPยฎ) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFAยฎ charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFPยฎ professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
โ ๏ธ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
